Anlon Healthcare Ltd

Anlon Healthcare Ltd. announced that Brickwork Ratings (BWR) has assigned a rating of BWR BBB / Stable to its Fund Based Long Term facilities amounting to Rs. 23.60 crore, alongside an assignment for Bank Loan facilities also rated BBB / Stable, while simultaneously removing a previous rating of BB+ Stable and withdrawing a rating of C from the ISSUER NOT COOPERATING* category; the rating agency also continues a rating of B- Stable under the ISSUER NOT COOPERATING* / Downgrade designation. The rating actions reflect Anlon Healthcare’s operating income of Rs. 176.54 crore for FY26, a net worth of Rs. 209.77 crore, and projected revenues of Rs. 270 crore for FY2027, alongside a moderate cash and bank balance of Rs. 3.41 crore, and net cash accruals of Rs. 30.92 crore, with no ratings assigned by RBI, SEBI, or MCA beyond those related to instruments originated or raised by other entities.

Anlon Healthcare Limited plans to acquire shares in Anlon Medicos Private Limited, a subsidiary, for Rs 500 Crore, alongside sales and purchases of goods and services also valued at Rs 500 Crore, representing 28.33% of the company’s turnover. The transactions, expected to strengthen manufacturing capacity and support long-term growth, are considered material and will be conducted at arm’s length pricing. Notably, Anlon Medicos currently holds a negative net worth of Rs 433.61 Lakhs as of March 31, 2026, and has reported a loss after tax of Rs 489.60 Lakhs for the same period, raising concerns about its financial viability. Directors Punitkumar Rasadia and Meet Atulkumar Vachhani, who hold positions in both companies, are considered interested parties in the proposed transactions, which are slated to continue until the next annual general meeting.

Anlon Healthcare Limited disclosed two related party transactions totaling Rs 5000 Lakhs (approximately $60 million USD) with Anlon Medicos Private Limited, fulfilling requirements outlined in SEBI regulations and circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026. The transactions, described as sales and purchases, represent 28.33% of Anlon Healthcare’s turnover and are considered commercially beneficial, supporting long-term growth plans. Directors Punitkumar Rasadia and Meet Atulkumar Vachhani have interests in the transactions, which are stated to be at arm’s length. Notably, Anlon Medicos Private Limited is a subsidiary of Anlon Healthcare, with AHL holding a 56.83% shareholding, and the related party reported a loss of Rs 489.60 Lakhs and a negative net worth of Rs 433.61 Lakhs, prompting scrutiny regarding the viability of the transactions. The second related party transaction appears to be a duplicate entry, and requires clarification.

Anlon Healthcare is undertaking a share swap with Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL) through a preferential allotment of equity shares, potentially issuing up to 8,58,83,617 shares at a price of Rs 17.85 per share. The swap ratio is 1 share of Anlon for 14.45 shares of AOPL, involving up to 160 shareholders and approximately 20,34,43,043 shares, while the ratio for BLPL is 1 share of Anlon for 8.96 shares, impacting up to 173 shareholders and roughly 22,99,000 shares. AOPL and BLPL operate within the pharmaceutical/organic and pharmaceutical/lifescience sectors, respectively, and both companies reported a turnover of Rs 380.39 crore in 2023-24, Rs 3,038.20 crore in 2024-25, and Rs 3,126.64 crore in 2025-26. The share swap will significantly increase the number of outstanding Anlon Healthcare shares, diluting existing shareholder ownership, and the final number of shares issued will depend on acceptance rates from shareholders of AOPL and BLPL.

Anlon Healthcare Limited has postponed its Board of Directors meeting, initially scheduled for Tuesday, August 11, 2026, to Thursday, August 13, 2026, due to administrative reasons, according to a regulatory filing with the BSE Limited and the National Stock Exchange of India Ltd.

Anlon Healthcare is undertaking a share swap with Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL) to strengthen relationships and potentially integrate operations, as detailed in filings with the Securities and Exchange Board of India. The swap involves a ratio of one Anlon share for 14.45 AOPL shares and one Anlon share for 8.96 BLPL shares, potentially issuing up to 8,58,83,617 new Anlon shares at an issue price of Rs. 17.85 per share. The transaction, which is voluntary for shareholders of AOPL and BLPL, will significantly increase the total number of outstanding Anlon shares and substantially increase the holdings of key shareholders Punitkumar Rameshbhai Rasadia and Meet Atulkumar Vachhani, potentially impacting the company’s control and governance. The rationale behind the specific swap ratios and planned integration strategies were not explicitly detailed.

Anlon Healthcare Limited will hold a board meeting on August 11, 2026, to approve the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and to consider the re-appointment of Mr. Punitkumar Rameshbhai Rasadia as a director. The board will also consider the issuance of equity shares on a preferential basis to shareholders of Apiqo Organics Private Limited and Bizotic Lifescience Private Limited, in lieu of the acquisition of their shares, and related party transactions with Apiqo Organics Private Limited, Bizotic Lifescience Private Limited, and Remember India Health Links Private Limited.

Anlon Healthcare Limited informed the BSE Limited and the National Stock Exchange of India Ltd. that the trading window for dealing in the company’s securities will be closed from Thursday, August 06, 2026, until Forty-Eight (48) hours from the conclusion of the Board of Directors meeting on Tuesday, August 11, 2026, in accordance with SEBI regulations and the company’s code of conduct for prevention of insider trading.

Anlon Healthcare Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026, reporting a total income of Rs 87.62 crore, a 163.02% year-on-year increase, with Rs 15.65 crore in EBITDA, up 150.14%, and Rs 8.28 crore in profit after tax, a 133.13% rise. The company acquired a 63.98% stake in Remember India Health Links Pvt. Ltd. for Rs 5.38 crore on May 8, 2026, expanding into the Finished Dosage Formulations (FDF) segment and gaining access to 30+ formulation dossiers, while also broadening its market presence across B2B APIs, domestic retail, and hospital markets.

Net profit of Anlon Healthcare rose 87.61% to Rs 6.66 crore in the quarter ended June 2026 as against Rs 3.55 crore during the previous quarter ended June 2025. Sales rose 162.94% to Rs 87.56 crore in the quarter ended June 2026 as against Rs 33.30 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales87.5633.30 163 OPM %17.8018.74 - PBDT14.735.43 171 PBT13.665.00 173 NP6.663.55 88 Powered by Capital Market - Live